This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Antares Pharma, NewLink, Celgene

Stocks in this article: ATRS CELG NLNK NWBO GALE DNDN IMUC BMY MRK

BOSTON ( TheStreet) -- Welcome back to Biotech Stock Mailbag.

Rahul A. writes:

What do you think about Antares Pharma (ATRS - Get Report)? It has a PDUFA date set for October 2013.

Antares Pharma develops new ways -- mainly self injections and rub-on skin gels -- to administer currently approved drugs. The company's lead product candidate is Otrexup -- an automatic self-injection device that comes pre-filled with methotrexate for use by patients with rheumatoid arthritis. Antares submitted Otrexup to the U.S. Food and Drug Administration last year, with an expected approval decision date of Oct. 14.

Methotrexate is a generic medicine, which, in pill form, is commonly prescribed to approximately 70% of the 1.5 million rheumatoid arthritis patients in the U.S. Injectable methotrexate is also available and delivers higher blood levels of the drug compared to pills. Despite its advantages, injectable methrotrexate is rarely prescribed, mainly because it requires a weekly visit to the doctor's office.

Antares believes the convenience of Otrexup -- patients can self inject at home -- will convince doctors to increase their use of injectable methotrexate for treating rheumatoid arthritis patients. If oral methotrexate is no longer effective, some patients might try Otrexup before moving on to biologic therapies like Abbvie's (ABBV) Humira, Amgen's (AMGN) Enbrel or Johnson & Johnson's (JNJ) Remicade.

First, FDA needs to approve Otrexup. Antares is not particularly transparent when it comes to sharing details of its drug development activities with investors. Most of the Otrexup data disclosures are press releases. Very little data have been presented at medical meetings or published in medical journals.

Methotrexate is already approved for rheumatoid arthritis and Antares doesn't change the drug used to fill its Otrexup self-injector device. This should work in the company's favor when it comes to FDA approval, as long as the agency is 1) copacetic with the self-injector device and 2) the efficacy and safety of Otrexup is comparable to injectable methotrexate using a conventional needle.

In August 2011, Antares issued a press release announcing positive results from a study demonstrating comparable performance between Otrexup and conventionally injected methotrexate. No details were provided in the press release. Reached this week, Antares spokeswoman Elaine Andrecovish says the study was never presented or published and data are not available.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs